Cutaneous squamous cell carcinoma

CSCC · Oncology · 1 drugs · 2 indications

Second most common skin cancer. Arises from squamous cells in the epidermis.

Competitive Landscape (1 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Libtayo	REGN	PD-1 inhibitor	Monoclonal antibody	IV	APPROVED

Indications (2)

Early-stage CSCC (neoadjuvant/adjuvant)

Advanced cutaneous squamous cell carcinoma

Libtayo APPROVED

Data from Supabase · Updated 2026-03-24